Roche Holding AG (RHHBY) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of a subcutaneous (SC) formulation of Lunsumio for the treatment of adults with follicular lymphoma.
The CHMP opinion is based on the Phase II GO29781 study, in which subcutaneous Lunsumio demonstrated pharmacokinetic non-inferiority compared to intravenous administration, with no unexpected safety signals.
The company said that data from the Phase II GO29781 study have been submitted to health authorities worldwide, including the U.S. Food and Drug Administration(FDA), for approval consideration.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.